Security
Aimei Health Technology Co., Ltd Ordinary Share · AFJK
AFJKNASDAQCommon stockCurrentCIK 1979005Updated Oct 20, 2026
AFJK price & chart
Loading TradingView…
NASDAQ:AFJK on TradingView ↗In the news
AIMEI HEALTH TECHNOLOGY CO., LTD RECEIVES NASDAQ NOTICE REGARDING DELAYED ANNUAL REPORT ↗
Recent filings
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 2.03, 9.01
DEF 14A filing
PRE 14A filing
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 2.03, 9.01
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 2.03, 9.01
Show 5 more recent filings
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01, 9.01
10-Q filing
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 2.03, 9.01
Termination of a Material Definitive Agreement · Regulation FD Disclosure
Items 1.02, 7.01, 9.01
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 2.03, 9.01
Financials
FY 2025 · USDSource
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| AssetsUSD | 45,468,518Source | 72,784,615Source | 12,532,359Source | 44,556,037Source | 71,921,531Source | 12,294,903Source | 43,602,847Source | 71,279,696Source | 12,103,039Source | 73,814,933Source | 70,470,565Source |
| Current assets: | |||||||||||
| Assets, CurrentUSD | 24,948Source | 123,900Source | 43,966Source | 44,638Source | 204,345Source | 18,707Source | 8,022Source | 480,716Source | 2,929Source | 30,384Source | 580,717Source |
| LIABILITIES AND EQUITY | |||||||||||
| LiabilitiesUSD | 3,464,428Source | 920,789Source | 4,528,684Source | 2,903,966Source | 801,215Source | 4,208,084Source | 2,375,746Source | 768,472Source | 4,061,660Source | 1,506,994Source | 714,841Source |
| Stockholders’ equity: | |||||||||||
| Common Stock, Value, IssuedUSD | 213Source | 213Source | 213Source | 213Source | 213Source | 213Source | 213Source | 213Source | 213Source | 213Source | 213Source |
| Retained Earnings (Accumulated Deficit)USD | -3,439,693Source | -797,102Source | -4,484,931Source | -2,859,541Source | -597,083Source | -4,189,590Source | -2,367,937Source | -287,969Source | -4,058,944Source | -1,476,823Source | -134,337Source |
| Stockholders' Equity Attributable to ParentUSD | -3,439,480Source | -796,889Source | -4,484,718Source | -2,859,328Source | -596,870Source | -4,189,377Source | -2,367,724Source | -287,756Source | -4,058,731Source | -1,476,610Source | -134,124Source |
| Liabilities and EquityUSD | 45,468,518Source | 72,784,615Source | 12,532,359Source | 44,556,037Source | 71,921,531Source | 12,294,903Source | 43,602,847Source | 71,279,696Source | 12,103,039Source | 73,814,933Source | 70,470,565Source |
| Current liabilities: | |||||||||||
| Liabilities, CurrentUSD | 2,774,428Source | 230,789Source | 3,838,684Source | 2,213,966Source | 111,215Source | 3,518,084Source | 1,685,746Source | 78,472Source | 3,371,660Source | 816,994Source | 24,841Source |
| Additional Financial Items | |||||||||||
| Accrued Liabilities, CurrentUSD | 292,609Source | 142,026Source | 513,316Source | 309,097Source | 59,412Source | 435,559Source | 457,420Source | 78,472Source | 447,997Source | 299,514Source | 24,841Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -74,613Source | -224,009Source | -565,100Source | -672,289Source |
| Cash flows from investing activities: | ||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -68,662Source | 30,787,800Source | 63,579,966Source | -277,700Source |
| Cash flows from financing activities: | ||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 158,862Source | -30,584,654Source | -63,040,145Source | 397,480Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 15,587Source | -20,863Source | -25,279Source | -552,509Source |
| Additional Financial Items | ||||||||||
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 352,019Source | 743,510Source | -83,144Source | 424,970Source | 45,440Source | 184,662Source | 1,059,768Source | 2,552,215Source |
| Nonoperating Income (Expense)USD | — | — | 482,171Source | 943,529Source | 109,204Source | 466,574Source | 107,424Source | 598,076Source | 1,895,527Source | 3,617,001Source |
| Operating Costs and ExpensesUSD | — | — | 130,152Source | 200,019Source | 192,348Source | 41,604Source | 61,984Source | 413,414Source | 835,759Source | 1,064,786Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -130,152Source | -200,019Source | -192,348Source | -41,604Source | -61,984Source | -413,414Source | -835,759Source | -1,064,786Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 352,019Source | 743,510Source | -83,144Source | 424,970Source | 45,440Source | 184,662Source | 1,059,768Source | 2,552,215Source |
| Additional Financial Items | ||||||||||
| Nonoperating Income (Expense)USD | — | — | 482,171Source | 943,529Source | 109,204Source | 466,574Source | 107,424Source | 598,076Source | 1,895,527Source | 3,617,001Source |
| Operating Costs and ExpensesUSD | — | — | 130,152Source | 200,019Source | 192,348Source | 41,604Source | 61,984Source | 413,414Source | 835,759Source | 1,064,786Source |
Filing attachments
ex99-1.htm · 8-K · 2026-07-08
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 AIMEI HEALTH TECHNOLOGY CO., LTD. ANNOUNCES TERMINATION OF BUSINESS COMBINATION AGREEMENT WITH UNITED HYDROGEN GROUP INC. Aimei Health Technology Co., Ltd. Announces Termination of Business Combination Agreement NEW YORK, July 8, 2026 - Aimei Health Technology Co., Ltd (NASDAQ: AFJK, AFJKU, AFJKR, the “Company”) announced today that it has terminated the Business Combination Agreement, dated as of June 19, 2024, as amended on June 6, 2025, with Un…
Read attachment ↗ex99-1.htm · 8-K · 2026-05-20
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 AIMEI HEALTH TECHNOLOGY CO., LTD RECEIVES NASDAQ NOTICE REGARDING DELAYED QUARTERLY REPORT New York, NY - May 20, 2026 - Aimei Health Technology Co., Ltd (the “Company”) (Nasdaq: AFJK) today announced that on May 19, 2026, it received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the peri…
Read attachment ↗ex99-1.htm · 8-K · 2026-04-21
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 AIMEI HEALTH TECHNOLOGY CO., LTD RECEIVES NASDAQ NOTICE REGARDING DELAYED ANNUAL REPORT New York, NY - April 21, 2026 - Aimei Health Technology Co., Ltd (the “Company”) (Nasdaq: AFJK) today announced that on April 17, 2026, it received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Annual Report on Form 10-K for the fiscal…
Read attachment ↗